Uremic encephalopathy refers to brain dysfunction induced by toxins in patients with rapid or long-term renal dysfunction, manifested by a decrease in glomerular filtration rate. Renal replacement therapy is a crucial treatment indication since it can result in a partial or total reversal of symptoms when started.
Epidemiology
Uremia is the condition in which encephalopathy becomes markedly severe and is uncommon in the progressive CKD state, because most patients receive renal replacement therapy before this condition sets in. It is found in various acute kidney injury cases which are linked to a rapid decrease in GFR (Glomerular filtration rate). Around 60% of CKD patients suffer from cognitive dysfunction relating means molecular damage, endothelial inflammation and nephrotoxicity. Uremic encephalopathy has a substantial impact on the morbidity and mortality of CKD patients, but dialysis and a kidney transplant can improve signs in acute kidney failure and end-stage kidney disease cases.
Anatomy
Pathophysiology
It is possible that glycine levels are increased in the cerebrospinal fluid and plasma, while the levels of GABA and glutamine decrease, which can lead to encephalopathy. Because guanidino compounds generated from L-arginine metabolism would trigger NMDA receptors as well as hinder GABA receptors, this could be a contributing factor. Vascular endothelial dysfunction has also been linked to cognitive dysfunction in encephalopathy. Reactive oxidant species may play a central role in UE development, and antioxidant drugs can halt RVLM activity. This exacerbates oxidative stress which leads to further production of uremic toxins, myelin injury and brain protein nitration.
Etiology
Uremic disease of brain results from uremic poisons build-up in patients with AKI or CKD. These poisons are majorly urea that is implicated and severe cognitive changes can occur when eGFR is less than 15 mL/min. In AKI patients, renal toxicity, prolonged hypotension, dehydration, sepsis, and hemorrhage may lead to increased levels of uremic toxins leading to acute kidney injury. On the other hand, in patients suffering from chronic kidney disease these may come from high level of uremicemia.
Genetics
Prognostic Factors
Encephalopathy uremic syndrome is usually accompanied by drowsiness, cognitive disturbance, and occasionally by asterixis. This phenomenon occurs when the dialysis treatment is commenced and the kidney functions are restored for the individuals with acute kidney injury. Furthermore, patients with permanent renal failure (ERSD) also can be relieved of these symptoms by dialysis or renal transplantation.
Diagnosing encephalopathy with reduced kidney function should be done as soon as possible to avoid complications. Among patients with kidney failure who start dialysis treatment promptly the mortality rates are reduced greatly.
Clinical History
Among youth children, there could be signs of irritability, poor behavior and trouble focusing. Children under the age of three may suffer from poor feeding skills and failure to thrive. Adolescents may exhibit the symptoms in the form of deterioration in academic performance or mood alteration.
In the case of an adult, symptoms are likely to develop into disorientation, drowsiness, and reduced level of awareness. “Flick tremor” or “asterixis” may be appreciable in some cases. Those who are already undergoing neurological treatments or have pre-existing conditions such as high blood pressure or diabetes could experience deterioration of cognitive abilities that may be more severe.
The existing display can vary from a patient with a gradual onset of kidney disease to a patient with acute kidney injury who has an abrupt onset. Chronic kidney disease patients may experience symptoms gradually throughout time as the kidney function deteriorates. On the other hand, the symptoms of the acute kidney injury may develop acutely and progression of the disease may be sudden.
Physical Examination
Physical Examination
During a physical examination, it is possible to detect cognitive dysfunction in patients characterized by abnormalities in memory, judgment, and the ability to perform calculations. Other symptoms that may be present include hyperreflexia, which is an exaggerated reflex response, asterixis, which is a tremor of the hand when the wrist is extended, papilledema, which is swelling of the optic disc in the eye, and nystagmus, which is involuntary eye movement.
Moreover, patients may also have neuropathy and myopathy. These symptoms are often associated with chronic kidney disease and uremic encephalopathy. In some cases, patients with CKD may experience a rapid decline in their estimated glomerular filtration rate (eGFR), leading to more severe symptoms of uremic encephalopathy. These symptoms may include confusion, delirium, seizures, disorientation, emotional volatility, and coma.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Drug toxicity
Hepatic encephalopathy
Hypoglycemia
Hypertensive encephalopathy
Wernicke-Korsakoff encephalopathy
Disequilibrium syndrome
Sepsis
Osmotic demyelination syndrome
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Uremic encephalopathy is a severe chronic kidney disease complication that can lead to neurological symptoms such as confusion, seizures, and coma. Renal replacement therapy (RRT) is a crucial intervention in managing uremic encephalopathy. However, managing CKD should also be implemented simultaneously, using various measures such as erythropoiesis-stimulating agents, calcium replacement, phosphate binders, and nutrition modification.
Intermittent hemodialysis (IHD) is more effective than continuous ambulatory peritoneal dialysis (CAPD) in managing uremic encephalopathy. However, the rapid osmotic changes that occur at the start of HD can lead to dialysis disequilibrium syndrome (DDS), a severe and potentially life-threatening complication. Mannitol is often used in the first few IHD sessions to prevent DDS.
Studies have shown that administering 25 grams of mannitol before dialysis can reduce the measured blood osmolality change by 60%. The plasma osmolality fall of 10 mmol/kg was decreased to 4.3 mmol/kg with intravenous mannitol. The use of mannitol also resulted in milder symptoms of DDS, which occurred in only 10% of patients, compared to 67% in the non-mannitol group, despite similar ultrafiltration rates.
Nutritional Support: Providing adequate nutrition and hydration is essential for patients with uremic encephalopathy.
Fluid Management: Maintaining appropriate fluid balance is crucial to prevent dehydration and electrolyte imbalances.
Dialysis: Renal replacement therapy, such as hemodialysis or peritoneal dialysis, is the cornerstone of treatment for uremic encephalopathy.
Temperature Regulation: Patients may have difficulty in regulating body temperature due to impaired sweating and thermoregulation.
Neurological Supportive Care: Creating a calm and quiet environment can minimize external stimuli and reduce agitation or confusion in patients.
Use of Ammonia Lowering Agents in the treatment of Uremic Encephalopathy
Lactulose: It is a synthetic sugar that is not absorbed by the body. When taken orally as it passes through the intestines and is broken down by bacteria which leads to the lactic acid production and other acids. These acids lower the pH in the intestines which helps convert ammonia (NH3) to ammonium (NH4+) which is a less toxic form.
Rifaximin: It is considered an antibiotic that function by diminishing the number of ammonia producing bacteria in the gut. Reduction of ammonia production by rifaximin results in lowering ammonia concentrations in the blood and ultimately decreasing the risk of neurological complications.
Use of Antiepileptic Drugs in the treatment of Uremic Encephalopathy
Levetiracetam: It is a drug intended to prevent seizures by altering neurotransmitter release within the brain. Various forms of seizures can be treated using it effectively.
Phenytoin: It is a traditional antiepileptic drug that works by stabilizing neuronal membranes and reducing the spread of seizure activity in the brain.
Renal replacement therapy plays an important role in the treatment of uremic encephalopathy by removing uremic toxins and maintaining the electrolyte imbalances.
Hemodialysis (HD): In hemodialysis the blood is removed from the body and passed through a dialyzer, a machine that acts as an artificial kidney. Hemodialysis is indicated in patients with uremic encephalopathy who have severe kidney dysfunction and are unable to adequately clear uremic toxins from their blood. Hemodialysis is typically performed several times a week, with each session lasting several hours, to maintain adequate clearance of toxins and eletrolytes.
Peritoneal Dialysis (PD): In peritoneal dialysis, a catheter is placed into the peritoneal cavity and a dialysate solution is introduced. Peritoneal dialysis may be used in patients with uremic encephalopathy who have acute kidney injury or end-stage renal disease and are unable to tolerate hemodialysis.
Continuous Renal Replacement Therapy (CRRT): Â It may be used in critically ill patients with uremic encephalopathy who require hemodynamic stability and more gentle fluid and solute removal. CRRT can help stabilize fluid balance and electrolytes while providing continuous clearance of uremic toxins which may be beneficial in patients with neurological symptoms.
use-of-phases-of-management
Uremic encephalopathy is a clinical condition arising from neurological features usually due to acute kidney injury or chronic kidney disease. Treatment of this disease includes hemodialysis or peritoneal dialysis aimed at correcting electrolyte imbalance and intense neurological support. Chronic kidney disease treatment plan with long-term prevention and care is a necessary element of the optimal management of the disease.
Uremic encephalopathy refers to brain dysfunction induced by toxins in patients with rapid or long-term renal dysfunction, manifested by a decrease in glomerular filtration rate. Renal replacement therapy is a crucial treatment indication since it can result in a partial or total reversal of symptoms when started.
Uremia is the condition in which encephalopathy becomes markedly severe and is uncommon in the progressive CKD state, because most patients receive renal replacement therapy before this condition sets in. It is found in various acute kidney injury cases which are linked to a rapid decrease in GFR (Glomerular filtration rate). Around 60% of CKD patients suffer from cognitive dysfunction relating means molecular damage, endothelial inflammation and nephrotoxicity. Uremic encephalopathy has a substantial impact on the morbidity and mortality of CKD patients, but dialysis and a kidney transplant can improve signs in acute kidney failure and end-stage kidney disease cases.
It is possible that glycine levels are increased in the cerebrospinal fluid and plasma, while the levels of GABA and glutamine decrease, which can lead to encephalopathy. Because guanidino compounds generated from L-arginine metabolism would trigger NMDA receptors as well as hinder GABA receptors, this could be a contributing factor. Vascular endothelial dysfunction has also been linked to cognitive dysfunction in encephalopathy. Reactive oxidant species may play a central role in UE development, and antioxidant drugs can halt RVLM activity. This exacerbates oxidative stress which leads to further production of uremic toxins, myelin injury and brain protein nitration.
Uremic disease of brain results from uremic poisons build-up in patients with AKI or CKD. These poisons are majorly urea that is implicated and severe cognitive changes can occur when eGFR is less than 15 mL/min. In AKI patients, renal toxicity, prolonged hypotension, dehydration, sepsis, and hemorrhage may lead to increased levels of uremic toxins leading to acute kidney injury. On the other hand, in patients suffering from chronic kidney disease these may come from high level of uremicemia.
Encephalopathy uremic syndrome is usually accompanied by drowsiness, cognitive disturbance, and occasionally by asterixis. This phenomenon occurs when the dialysis treatment is commenced and the kidney functions are restored for the individuals with acute kidney injury. Furthermore, patients with permanent renal failure (ERSD) also can be relieved of these symptoms by dialysis or renal transplantation.
Diagnosing encephalopathy with reduced kidney function should be done as soon as possible to avoid complications. Among patients with kidney failure who start dialysis treatment promptly the mortality rates are reduced greatly.
Among youth children, there could be signs of irritability, poor behavior and trouble focusing. Children under the age of three may suffer from poor feeding skills and failure to thrive. Adolescents may exhibit the symptoms in the form of deterioration in academic performance or mood alteration.
In the case of an adult, symptoms are likely to develop into disorientation, drowsiness, and reduced level of awareness. “Flick tremor” or “asterixis” may be appreciable in some cases. Those who are already undergoing neurological treatments or have pre-existing conditions such as high blood pressure or diabetes could experience deterioration of cognitive abilities that may be more severe.
The existing display can vary from a patient with a gradual onset of kidney disease to a patient with acute kidney injury who has an abrupt onset. Chronic kidney disease patients may experience symptoms gradually throughout time as the kidney function deteriorates. On the other hand, the symptoms of the acute kidney injury may develop acutely and progression of the disease may be sudden.
Physical Examination
During a physical examination, it is possible to detect cognitive dysfunction in patients characterized by abnormalities in memory, judgment, and the ability to perform calculations. Other symptoms that may be present include hyperreflexia, which is an exaggerated reflex response, asterixis, which is a tremor of the hand when the wrist is extended, papilledema, which is swelling of the optic disc in the eye, and nystagmus, which is involuntary eye movement.
Moreover, patients may also have neuropathy and myopathy. These symptoms are often associated with chronic kidney disease and uremic encephalopathy. In some cases, patients with CKD may experience a rapid decline in their estimated glomerular filtration rate (eGFR), leading to more severe symptoms of uremic encephalopathy. These symptoms may include confusion, delirium, seizures, disorientation, emotional volatility, and coma.
Drug toxicity
Hepatic encephalopathy
Hypoglycemia
Hypertensive encephalopathy
Wernicke-Korsakoff encephalopathy
Disequilibrium syndrome
Sepsis
Osmotic demyelination syndrome
Uremic encephalopathy is a severe chronic kidney disease complication that can lead to neurological symptoms such as confusion, seizures, and coma. Renal replacement therapy (RRT) is a crucial intervention in managing uremic encephalopathy. However, managing CKD should also be implemented simultaneously, using various measures such as erythropoiesis-stimulating agents, calcium replacement, phosphate binders, and nutrition modification.
Intermittent hemodialysis (IHD) is more effective than continuous ambulatory peritoneal dialysis (CAPD) in managing uremic encephalopathy. However, the rapid osmotic changes that occur at the start of HD can lead to dialysis disequilibrium syndrome (DDS), a severe and potentially life-threatening complication. Mannitol is often used in the first few IHD sessions to prevent DDS.
Studies have shown that administering 25 grams of mannitol before dialysis can reduce the measured blood osmolality change by 60%. The plasma osmolality fall of 10 mmol/kg was decreased to 4.3 mmol/kg with intravenous mannitol. The use of mannitol also resulted in milder symptoms of DDS, which occurred in only 10% of patients, compared to 67% in the non-mannitol group, despite similar ultrafiltration rates.
Nephrology
Nutritional Support: Providing adequate nutrition and hydration is essential for patients with uremic encephalopathy.
Fluid Management: Maintaining appropriate fluid balance is crucial to prevent dehydration and electrolyte imbalances.
Dialysis: Renal replacement therapy, such as hemodialysis or peritoneal dialysis, is the cornerstone of treatment for uremic encephalopathy.
Temperature Regulation: Patients may have difficulty in regulating body temperature due to impaired sweating and thermoregulation.
Neurological Supportive Care: Creating a calm and quiet environment can minimize external stimuli and reduce agitation or confusion in patients.
Nephrology
Lactulose: It is a synthetic sugar that is not absorbed by the body. When taken orally as it passes through the intestines and is broken down by bacteria which leads to the lactic acid production and other acids. These acids lower the pH in the intestines which helps convert ammonia (NH3) to ammonium (NH4+) which is a less toxic form.
Rifaximin: It is considered an antibiotic that function by diminishing the number of ammonia producing bacteria in the gut. Reduction of ammonia production by rifaximin results in lowering ammonia concentrations in the blood and ultimately decreasing the risk of neurological complications.
Nephrology
Levetiracetam: It is a drug intended to prevent seizures by altering neurotransmitter release within the brain. Various forms of seizures can be treated using it effectively.
Phenytoin: It is a traditional antiepileptic drug that works by stabilizing neuronal membranes and reducing the spread of seizure activity in the brain.
Nephrology
Renal replacement therapy plays an important role in the treatment of uremic encephalopathy by removing uremic toxins and maintaining the electrolyte imbalances.
Hemodialysis (HD): In hemodialysis the blood is removed from the body and passed through a dialyzer, a machine that acts as an artificial kidney. Hemodialysis is indicated in patients with uremic encephalopathy who have severe kidney dysfunction and are unable to adequately clear uremic toxins from their blood. Hemodialysis is typically performed several times a week, with each session lasting several hours, to maintain adequate clearance of toxins and eletrolytes.
Peritoneal Dialysis (PD): In peritoneal dialysis, a catheter is placed into the peritoneal cavity and a dialysate solution is introduced. Peritoneal dialysis may be used in patients with uremic encephalopathy who have acute kidney injury or end-stage renal disease and are unable to tolerate hemodialysis.
Continuous Renal Replacement Therapy (CRRT): Â It may be used in critically ill patients with uremic encephalopathy who require hemodynamic stability and more gentle fluid and solute removal. CRRT can help stabilize fluid balance and electrolytes while providing continuous clearance of uremic toxins which may be beneficial in patients with neurological symptoms.
Nephrology
Uremic encephalopathy is a clinical condition arising from neurological features usually due to acute kidney injury or chronic kidney disease. Treatment of this disease includes hemodialysis or peritoneal dialysis aimed at correcting electrolyte imbalance and intense neurological support. Chronic kidney disease treatment plan with long-term prevention and care is a necessary element of the optimal management of the disease.
Uremic encephalopathy refers to brain dysfunction induced by toxins in patients with rapid or long-term renal dysfunction, manifested by a decrease in glomerular filtration rate. Renal replacement therapy is a crucial treatment indication since it can result in a partial or total reversal of symptoms when started.
Uremia is the condition in which encephalopathy becomes markedly severe and is uncommon in the progressive CKD state, because most patients receive renal replacement therapy before this condition sets in. It is found in various acute kidney injury cases which are linked to a rapid decrease in GFR (Glomerular filtration rate). Around 60% of CKD patients suffer from cognitive dysfunction relating means molecular damage, endothelial inflammation and nephrotoxicity. Uremic encephalopathy has a substantial impact on the morbidity and mortality of CKD patients, but dialysis and a kidney transplant can improve signs in acute kidney failure and end-stage kidney disease cases.
It is possible that glycine levels are increased in the cerebrospinal fluid and plasma, while the levels of GABA and glutamine decrease, which can lead to encephalopathy. Because guanidino compounds generated from L-arginine metabolism would trigger NMDA receptors as well as hinder GABA receptors, this could be a contributing factor. Vascular endothelial dysfunction has also been linked to cognitive dysfunction in encephalopathy. Reactive oxidant species may play a central role in UE development, and antioxidant drugs can halt RVLM activity. This exacerbates oxidative stress which leads to further production of uremic toxins, myelin injury and brain protein nitration.
Uremic disease of brain results from uremic poisons build-up in patients with AKI or CKD. These poisons are majorly urea that is implicated and severe cognitive changes can occur when eGFR is less than 15 mL/min. In AKI patients, renal toxicity, prolonged hypotension, dehydration, sepsis, and hemorrhage may lead to increased levels of uremic toxins leading to acute kidney injury. On the other hand, in patients suffering from chronic kidney disease these may come from high level of uremicemia.
Encephalopathy uremic syndrome is usually accompanied by drowsiness, cognitive disturbance, and occasionally by asterixis. This phenomenon occurs when the dialysis treatment is commenced and the kidney functions are restored for the individuals with acute kidney injury. Furthermore, patients with permanent renal failure (ERSD) also can be relieved of these symptoms by dialysis or renal transplantation.
Diagnosing encephalopathy with reduced kidney function should be done as soon as possible to avoid complications. Among patients with kidney failure who start dialysis treatment promptly the mortality rates are reduced greatly.
Among youth children, there could be signs of irritability, poor behavior and trouble focusing. Children under the age of three may suffer from poor feeding skills and failure to thrive. Adolescents may exhibit the symptoms in the form of deterioration in academic performance or mood alteration.
In the case of an adult, symptoms are likely to develop into disorientation, drowsiness, and reduced level of awareness. “Flick tremor” or “asterixis” may be appreciable in some cases. Those who are already undergoing neurological treatments or have pre-existing conditions such as high blood pressure or diabetes could experience deterioration of cognitive abilities that may be more severe.
The existing display can vary from a patient with a gradual onset of kidney disease to a patient with acute kidney injury who has an abrupt onset. Chronic kidney disease patients may experience symptoms gradually throughout time as the kidney function deteriorates. On the other hand, the symptoms of the acute kidney injury may develop acutely and progression of the disease may be sudden.
Physical Examination
During a physical examination, it is possible to detect cognitive dysfunction in patients characterized by abnormalities in memory, judgment, and the ability to perform calculations. Other symptoms that may be present include hyperreflexia, which is an exaggerated reflex response, asterixis, which is a tremor of the hand when the wrist is extended, papilledema, which is swelling of the optic disc in the eye, and nystagmus, which is involuntary eye movement.
Moreover, patients may also have neuropathy and myopathy. These symptoms are often associated with chronic kidney disease and uremic encephalopathy. In some cases, patients with CKD may experience a rapid decline in their estimated glomerular filtration rate (eGFR), leading to more severe symptoms of uremic encephalopathy. These symptoms may include confusion, delirium, seizures, disorientation, emotional volatility, and coma.
Drug toxicity
Hepatic encephalopathy
Hypoglycemia
Hypertensive encephalopathy
Wernicke-Korsakoff encephalopathy
Disequilibrium syndrome
Sepsis
Osmotic demyelination syndrome
Uremic encephalopathy is a severe chronic kidney disease complication that can lead to neurological symptoms such as confusion, seizures, and coma. Renal replacement therapy (RRT) is a crucial intervention in managing uremic encephalopathy. However, managing CKD should also be implemented simultaneously, using various measures such as erythropoiesis-stimulating agents, calcium replacement, phosphate binders, and nutrition modification.
Intermittent hemodialysis (IHD) is more effective than continuous ambulatory peritoneal dialysis (CAPD) in managing uremic encephalopathy. However, the rapid osmotic changes that occur at the start of HD can lead to dialysis disequilibrium syndrome (DDS), a severe and potentially life-threatening complication. Mannitol is often used in the first few IHD sessions to prevent DDS.
Studies have shown that administering 25 grams of mannitol before dialysis can reduce the measured blood osmolality change by 60%. The plasma osmolality fall of 10 mmol/kg was decreased to 4.3 mmol/kg with intravenous mannitol. The use of mannitol also resulted in milder symptoms of DDS, which occurred in only 10% of patients, compared to 67% in the non-mannitol group, despite similar ultrafiltration rates.
Nephrology
Nutritional Support: Providing adequate nutrition and hydration is essential for patients with uremic encephalopathy.
Fluid Management: Maintaining appropriate fluid balance is crucial to prevent dehydration and electrolyte imbalances.
Dialysis: Renal replacement therapy, such as hemodialysis or peritoneal dialysis, is the cornerstone of treatment for uremic encephalopathy.
Temperature Regulation: Patients may have difficulty in regulating body temperature due to impaired sweating and thermoregulation.
Neurological Supportive Care: Creating a calm and quiet environment can minimize external stimuli and reduce agitation or confusion in patients.
Nephrology
Lactulose: It is a synthetic sugar that is not absorbed by the body. When taken orally as it passes through the intestines and is broken down by bacteria which leads to the lactic acid production and other acids. These acids lower the pH in the intestines which helps convert ammonia (NH3) to ammonium (NH4+) which is a less toxic form.
Rifaximin: It is considered an antibiotic that function by diminishing the number of ammonia producing bacteria in the gut. Reduction of ammonia production by rifaximin results in lowering ammonia concentrations in the blood and ultimately decreasing the risk of neurological complications.
Nephrology
Levetiracetam: It is a drug intended to prevent seizures by altering neurotransmitter release within the brain. Various forms of seizures can be treated using it effectively.
Phenytoin: It is a traditional antiepileptic drug that works by stabilizing neuronal membranes and reducing the spread of seizure activity in the brain.
Nephrology
Renal replacement therapy plays an important role in the treatment of uremic encephalopathy by removing uremic toxins and maintaining the electrolyte imbalances.
Hemodialysis (HD): In hemodialysis the blood is removed from the body and passed through a dialyzer, a machine that acts as an artificial kidney. Hemodialysis is indicated in patients with uremic encephalopathy who have severe kidney dysfunction and are unable to adequately clear uremic toxins from their blood. Hemodialysis is typically performed several times a week, with each session lasting several hours, to maintain adequate clearance of toxins and eletrolytes.
Peritoneal Dialysis (PD): In peritoneal dialysis, a catheter is placed into the peritoneal cavity and a dialysate solution is introduced. Peritoneal dialysis may be used in patients with uremic encephalopathy who have acute kidney injury or end-stage renal disease and are unable to tolerate hemodialysis.
Continuous Renal Replacement Therapy (CRRT): Â It may be used in critically ill patients with uremic encephalopathy who require hemodynamic stability and more gentle fluid and solute removal. CRRT can help stabilize fluid balance and electrolytes while providing continuous clearance of uremic toxins which may be beneficial in patients with neurological symptoms.
Nephrology
Uremic encephalopathy is a clinical condition arising from neurological features usually due to acute kidney injury or chronic kidney disease. Treatment of this disease includes hemodialysis or peritoneal dialysis aimed at correcting electrolyte imbalance and intense neurological support. Chronic kidney disease treatment plan with long-term prevention and care is a necessary element of the optimal management of the disease.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
